Prapid 10 mg (Tablet)
Unit Price: ৳ 20.10 (2 x 10: ৳ 402.00)
Strip Price: ৳ 201.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Prasugrel hydrochloride |
| Company | Drug international ltd |
| Also available as |
Indications
- Reduces rate of thrombotic cardiovascular events
- Indicated for acute coronary syndrome (ACS)
- Management with percutaneous coronary intervention (PCI)
- For patients with unstable angina (UA) or non-ST-elevation myocardial infarction (NSTEMI)
- For patients with ST-elevation myocardial infarction (STEMI)
Pharmacology
- Inhibitor of platelet activation and aggregation
- Irreversible binding to P2Y12 class of ADP receptors
Dosage & Administration
- Initiate with a single 60 mg oral loading dose
- Continue at 10 mg once daily
- Consider 5 mg once daily for patients <60 kg
- Should be taken with or without food
- Patients should also take aspirin daily
Interaction
- Coadministration with warfarin increases risk of bleeding
- Coadministration with NSAIDs may increase risk of bleeding
- Can be administered with drugs that are inducers or inhibitors of cytochrome P450 enzymes
- Can be administered with aspirin, heparin, GPIIb/IIIa inhibitors, statins, and drugs that elevate gastric pH
Contraindications
- Active pathological bleeding
- History of prior transient ischemic attack or stroke
Side Effects
- Bleeding
- Thrombotic thrombocytopenic purpura
- Other side effects such as headache, back pain, dyspnea, nausea, hypertension, bradycardia, rash
Pregnancy & Lactation
- No adequate and well-controlled studies in pregnant women
- Reproductive and developmental toxicology studies in animals showed no evidence of fetal harm
- Not known if excreted in human milk
- Should be used during nursing only if the potential benefit justifies the potential risk
Precautions & Warnings
- CABG-related bleeding risk increases
- Premature discontinuation increases risk of stent thrombosis, MI, and death
Use in Special Populations
- Safety and effectiveness in pediatric patients not established
- Increased risk of fatal bleeding events in patients >75 years of age
- No dosage adjustment necessary for patients with renal impairment
- Limited experience in patients with end-stage renal disease
- No dosage adjustment necessary in patients with mild to moderate hepatic impairment
Overdose Effects
- Lethality observed in rats after administration of high dose
- Platelet transfusion may restore clotting ability
- Active metabolite not likely to be removed by dialysis
Therapeutic Class
- Anti-platelet drugs
Storage Conditions
- Keep in dry place
- Away from light and heat
- Keep out of the reach of children